Aileron Therapeutics, Inc. (ALRN) Income Statement Analysis

See more : Rio Tinto Group (RIO.L) Income Statement Analysis – Financial Results

Complete financial analysis of Aileron Therapeutics, Inc. (ALRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aileron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Aileron Therapeutics, Inc. (ALRN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.aileronrx.com

About Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.35M
Cost of Revenue	119.00K	169.00K	121.00K	163.00K	155.00K	218.00K	95.00K	232.00K	325.00K	9.33M	12.23M
Gross Profit	-119.00K	-169.00K	-121.00K	-163.00K	-155.00K	-218.00K	-95.00K	-232.00K	-325.00K	-9.33M	10.12M
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	45.29%
Research & Development	3.99M	17.97M	17.01M	11.17M	17.66M	18.45M	14.24M	10.28M	7.83M	9.33M	12.23M
General & Administrative	11.36M	9.68M	9.60M	9.33M	12.29M	13.45M	8.77M	7.89M	5.06M	6.70M	6.84M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	11.36M	9.68M	9.60M	9.33M	12.29M	13.45M	8.77M	7.89M	5.06M	6.70M	6.84M
Other Expenses	928.00K	318.00K	441.00K	-800.00K	0.00	0.00	0.00	-18.17M	0.00	0.00	0.00
Operating Expenses	16.28M	27.65M	26.61M	20.50M	29.96M	31.90M	23.01M	18.17M	12.89M	6.70M	6.84M
Cost & Expenses	16.28M	27.65M	26.61M	20.50M	29.96M	31.90M	23.01M	18.17M	12.89M	16.03M	19.07M
Interest Income	0.00		0.00	0.00	587.00K	355.00K	404.00K	46.00K	13.00K	10.00K	6.00K
Interest Expense	0.00		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	119.00K	169.00K	121.00K	163.00K	155.00K	218.00K	95.00K	232.00K	325.00K	585.00K	774.00K
EBITDA	-15.61M	-27.48M	-26.48M	-20.33M	-29.80M	-31.33M	-23.01M	-17.94M	-12.57M	-15.44M	4.06M
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	18.16%
Operating Income	-16.28M	-27.65M	-26.61M	-20.50M	-29.96M	-31.90M	-23.01M	-18.17M	-12.89M	-16.03M	3.28M
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14.69%
Total Other Income/Expenses	544.00K	318.00K	441.00K	-661.00K	587.00K	355.00K	404.00K	46.00K	13.00K	10.00K	6.00K
Income Before Tax	-15.73M	-27.33M	-26.21M	-21.16M	-29.37M	-31.55M	-22.60M	-18.12M	-12.88M	-16.02M	3.29M
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14.72%
Income Tax Expense	0.00	-318.00K	-441.00K	661.00K	-587.00K	355.00K	34.00K	0.00	0.00	43.00K	3.10M
Net Income	-15.73M	-27.01M	-25.76M	-21.82M	-28.78M	-31.55M	-22.60M	-18.12M	-12.88M	-16.07M	194.00K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.87%
EPS	-3.42	-5.95	-5.80	-12.52	-23.46	-42.81	-60.74	-33.21	-23.60	-845.63	10.21
EPS Diluted	-3.42	-5.95	-5.80	-12.52	-23.46	-42.81	-60.74	-33.21	-23.60	-844.96	10.85
Weighted Avg Shares Out	4.60M	4.54M	4.44M	1.74M	1.23M	736.91K	372.15K	545.72K	545.72K	19.00K	19.00K
Weighted Avg Shares Out (Dil)	4.60M	4.54M	4.44M	1.74M	1.23M	736.91K	372.15K	545.72K	545.72K	19.02K	17.89K

The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs

June 2, 2020benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC...

The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant

May 29, 2020benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE:...

Aileron Communications Announces Promotions

May 12, 2020businesswire.com

Aileron Communications, a strategic communications agency specializing in complex, high-stakes engagements, announced today the promotions of Peter Gr

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX)

May 1, 2020smarteranalyst.com

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN) and Dynavax (DVAX) with

Aileron Therapeutics (ALRN) Receives a Buy from H.C. Wainwright

April 27, 2020smarteranalyst.com

H.C. Wainwright analyst Edward White reiterated a Buy rating on Aileron Therapeutics (ALRN) on April 22 and set a price target of $3.00. The company's

JonesTrading Thinks Aileron Therapeutics' Stock is Going to Recover

April 8, 2020smarteranalyst.com

JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company's

Analysts' Top Healthcare Picks: Aileron Therapeutics (ALRN), Mersana Therapeutics (MRSN)

March 31, 2020smarteranalyst.com

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aileron Therapeutics (ALRN) and Mersana Therapeutics (MRSN)

The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

March 13, 2020benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

March 12, 2020benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...